Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours

A Stradella, ML Johnson, S Goel, SR Chandana, MD Galsky, E Calvo, V Moreno, H Park, H-T Arkenau, A Cervantes, L Fariñas Madrid, L Mileshkin, R Plummer, J Evans, L Horvath, A Prawira, RJ Pelham, S Mu, C Andreu-Vieyra, M Barve